Search clinical trials for: Lenvatinib, Tislelizumab Combined with RALOX Regimen HAIC

Total 97 results

Guangdong Provincial People's Hospital

Recruiting

Lenvatinib, Tislelizumab Combined With RALOX Regimen HAIC in Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Guangxi Medical University

Completed

HAIC Sequential TAE Combined With Lenvatinib and Tislelizumab in Unresectable HCC (FRONT-1)

Liver Cancer

China
Sun Yat-sen University

Recruiting

Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC (TALENT)

Recurrent Hepatocellular Carcinoma

China
Wen Li

Recruiting

HAIC+Lenvatinib+Tislelizumab vs D-TACE+Lenvatinib+Tislelizumab for Unresectable HCC

Unresectable Hepatocellular Carcinoma

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Tislelizumab Combined With Lenvatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma

Resectable Hepatocellular Carcinoma

China
XIANG YANQUN

Recruiting

Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis.

Nasopharyngeal Carcinoma

China
Wuhan Union Hospital, China

Recruiting

The Study of Vidicizumab Combined With Tirelizumab in the Treatment of Breast Cancer With Low HER2 Expression

Breast Cancer | Neoadjuvant Therapy

China
Fudan University

Recruiting

Tislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC

Nasopharyngeal Carcinoma

China
Cancer Hospital of Guangxi Medical University

Active, not recruiting

Clinical Study of the Efficacy and Safety of Transhepatic Arterial Chemoembolization Combined With Tislelizumab and Lenvatinib in Patients With Advanced Unresectable Hepatocellular Carcinoma

TACE | Lenvatinib | Tislelizumab | Advanced Unresectable Hepatocellular Carcinoma

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

Phase III Study of Toripalimab（JS001） Combined With Lenvatinib for Advanced HCC

Advanced Hepatocellular Carcinoma (HCC)

Italy, Poland, Singapore, United States, China, Ukraine
Zhejiang Cancer Hospital

Recruiting

GOT Applied as Neoadjuvant Regimen for Patients of Resectable ICC With High-risk Factors of Recurrence (GOT)

Intrahepatic Cholangiocarcinoma

China
Fudan University

Recruiting

Capecitabine Combined With Lenvatinib and Tislelizumab as Adjuvant Treatment After Resection in Patients With BTC

Biliary Tract Cancer

China
Ruijin Hospital

Not yet recruiting

Safety and Efficacy of BCG Combined With Tislelizumab for BCG-untreated Patients With High-risk Non-muscle Invasive Bladder Cancer

Non-muscle-invasive Bladder Cancer

China
Zhongda Hospital

Recruiting

HAIC Combined With Donafenib and Sintilimab for Unresectable ICC

Cholangiocarcinoma

China
Peking University Cancer Hospital & Institute
Innovent Biologics (Suzhou) Co. Ltd.

Completed

HAIC Combined Sintilimab for Liver Metastasis From Esophageal Squamous Cell Carcinoma

Liver Metastases | Esophageal Squamous Cell Carcinoma | Hepatic Arterial Infusion Chemotherapy

China
Ningbo No. 1 Hospital
Zhejiang University

Recruiting

CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL

Diffuse Large B-cell Lymphoma

China
Binkui Li

Recruiting

HAIC Combined With Sintilimab and Bevacizumab for Unresectable Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma

China
Yunfei Yuan

Recruiting

HAIC Combined With Tislelizumab and Apatinib for Unresectable Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma

China
Shanghai Zhongshan Hospital

Active, not recruiting

Two-cohort Study of Toripalimab(PD1)+Lenvatnib, or Gemox+Lenvatinib in Advanced Intrahepatic Cholangiocarcinoma

Cholangiocarcinoma, Intrahepatic

China
RenJi Hospital

Recruiting

Combination of RC48 and Tislelizumab for Renal Preservation in High-risk UTUC Patients

Upper Urinary Tract Urothelial Carcinoma | Kidney Preservation | HER-2 ADC | PD-1antibody

China
Yang Jianjun, PhD

Recruiting

Adebrelimab Combined With SOX Regimen in Preoperative Neoadjuvant Transformation Therapy for Locally Advanced Gastric Adenocarcinoma

Locally Advanced Gastric Adenocarcinoma

China
First Affiliated Hospital of Guangxi Medical University

Recruiting

The Effects of Neoadjuvant Tislelizumab Combined With Chemotherapy in Locally Advanced MSS Rectal Cancer

Rectal Cancer | Rectal Cancer Stage II | Rectal Cancer Stage III

China
The First Affiliated Hospital of Xinxiang Medical...
BeiGene

Not yet recruiting

Efficacy and Safety of Tislelizumab and Nab-paclitaxel Combined With Low-dose Radiotherapy in Patients With Stage IVb Esophageal Squamous Cell Carcinoma

ESCC
Chen Xiaoping

Not yet recruiting

Efficacy and Safety of Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model.

HCC
The First Affiliated Hospital with Nanjing Medical...

Not yet recruiting

Evaluation of The Efficacy And Safety of PD-1 + IL-2 Combined With Capox Treatment After Loop Colostomy Surgery in Left-sided Colorectal Cancer Patients Complicating Acute Obstruction

Left-sided Colorectal Cancer Complicating Acute Obstruction
Guangxi Medical University

Completed

TACE Combined With Donafenib and Tislelizumab in Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
First Affiliated Hospital, Sun Yat-Sen University

Not yet recruiting

TACE Plus HAIC Combined With Regorafenib for Liver Metastasis of Colorectal Cancer Refractory to Standard Treatment Regimens

Liver Metastasis Colon Cancer

China
Immix Biopharma, Inc.
Novartis; BeiGene

Recruiting

Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid Tumors (IMMINENT-01)

Advanced Solid Tumor

Brazil
Sun Yat-sen University

Recruiting

The Efficacy of Hepatic Arterial Infusion Chemotherapy (HAIC) Combine Lenvatinib and Durvalumab (HILL) in Advanced Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma

China
First Affiliated Hospital of Guangxi Medical University

Recruiting

Tislelizumab Combined With Concurrent Chemoradiotherapy as First-line Treatment for Stage IIIC2 Cervical Cancer

Cervical Cancer

China
Sun Yat-sen University

Recruiting

Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC

Clear Cell Renal Cell Carcinoma | Neoadjuvant Therapy | Cadonilimab

China
Sun Yat-sen University

Not yet recruiting

Pucotenlimab Combined With Lenvatinib as a Neodjuvant Therapy for Non Clear Cell Renal Cell Carcinoma

Renal Cell Carcinoma

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

Exploratory Study on Combined Conversion Immunotherapy for Liver Metastasis of MSS Type Initial Unresectable Colorectal Cancer Based on Gene Status

Colorectal Cancer | Liver Metastases

China
Sichuan University

Not yet recruiting

The Effectiveness and Safety of Camrelizumab/Lenvatinib Combined With TACE in Patients With Borderline Resectable HCC

Carrelizumab Plus Lenvatinib Combined With TACE | Borderline Resectable Hepatocellular Carcinoma

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Phase Ib/II Trail of Neoadjuvant of Tislelizumab Combined With Palbociclib in Patients With Platinum-refractory Bladder Urothelial Carcinoma

Bladder Cancer

China
Fujian Medical University

Recruiting

A Study on the Safety and Efficacy of the Combination of Candenizumab, Lenvatinib, and SOX Regimen in the Treatment of HER2 Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Patients

Overall Response Rate

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Envafolimab, Lenvatinib Combined With TACE in the Treatment of Unresectable Locally Advanced Hepatocellular Carcinoma

Objective Response Rate (ORR)
Second Affiliated Hospital of Guangzhou Medical...

Completed

TACE Combined With Lenvatinib and Sintilimab for Advanced HCC

Hepatocellular Carcinoma Non-resectable

China
Renmin Hospital of Wuhan University

Completed

First-line Apatinib Combined With Tislelizumab and Chemotherapy for Advanced GC (RENMIN-213)

Advanced Gastric Adenocarcinoma

China
Hunan Province Tumor Hospital

Recruiting

JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer

Small-cell Lung Cancer

China
Fudan University

Recruiting

Hepatic Arterial Infusion Chemotherapy Combined With Sintilimab and Regorafenib as Adjuvant Therapy for Colorectal Liver Metastasis Patients With a High Risk of Recurrent: a Single-arm, Phase II Study

Colorectal Liver Metastasis

China
Sun Yat-sen University

Recruiting

TACE Combined With Lenvatinib and MWA in the Treatment of Locally Advanced Large Hepatocellular Carcinoma

Liver Tumor

China
Jian Chen

Recruiting

Clinical Study of Postoperative Carbon Ion Radiotherapy for Thymus Tumor With Residual Tumor

Thymic Epithelial Tumor | Radiotherapy Side Effect | Carbon Ion Radiotheray | Heavy Ion Radiotherapy

China
Shandong Cancer Hospital and Institute

Recruiting

Tislelizumab Combined With Neoadjuvant Radiotherapy and Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma.

Advanced Esophageal Squamous Cell Cancer

China
Tianjin Medical University Cancer Institute and...

Unknown

PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of HCC (PLTHCC)

Hepatocellular Carcinoma Non-resectable

China
Sun Yat-sen University

Recruiting

Neoadjuvant Therapy of GP Chemotherapy Combined With Tislelizumab in Locoregionally Advanced NPC

Nasopharyngeal Carcinoma

China
Wen Tianfu

Recruiting

Lenvatinib Combined With TACE and Camrelizumab in Conversion Resection for Advanced Hepatocellular Carcinoma (LEN-TAC Study)

Advanced Hepatocellular Carcinoma

China
Fudan University

Recruiting

Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC

HER2-positive Gastric Cancer | Immunotherapy

China
University of Arkansas

Active, not recruiting

A Phase I/II Clinical Trial of PepCan in Head and Neck Cancer Patients

Head and Neck Cancer

United States
Second Affiliated Hospital of Guangzhou Medical...

Recruiting

TACE Plus Multikinase Inhibitor and I-125 Seeds Brachytherapy for HCC With Branch PVTT

Hepatocellular Carcinoma Non-resectable

China

3

Subscribe